期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

丹参酮IIa联合阿托伐他汀治疗2型糖尿病患者颈动脉粥样硬化疗效观察 被引量：2

下载PDF
导出
摘要 糖尿病是冠心病的等危症已成共识。如何有效控制糖尿病大血管并发症是现在临床研究的重点。动脉粥样硬化是大血管病主要的病理学基础。作者使用丹参酮IIa联合阿托伐他汀治疗2型糖尿病患者动脉粥样斑块，以颈动脉为观察重点，取得了较好的效果。现报道如下。
作者 范国平 顾占学
机构地区 浙江省桐乡市第三人民医院内分泌科
出处 《浙江临床医学》 2014年第1期95-96,共2页 Zhejiang Clinical Medical Journal
关键词 颈动脉粥样硬化 丹参酮IIA 2型糖尿病 阿托伐他汀 疗效观察 患者 治疗 糖尿病大血管并发症
分类号 R543.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1BarthJD. An update on carotid ultrasound measurement ofintimaemediu thickness. AMJ Cardiol, 2002, 49(4A): 32B-38B.
  • 2Crouse JR, Harpold GH, Kanl FR, et al. Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. Stroke, 1986, 17: 270-275.
  • 3孙明谨,李雪锋,陈世清,胡清,王芳,朱大菊.2型糖尿病血清C反应蛋白及血白细胞变化[J].中国医师杂志,2005,7(11):1557-1558. 被引量：19
  • 4Ross R. Atherosclemsis an inflammastory disease. New Engl J med. 1999, 340(2):115-126.
  • 5王树凤.丹参酮IIA磺酸钠治疗对2型糖尿病患者炎性标志物的影响[J].中国现代药物应用,2009,3(10):66-67. 被引量：7
  • 6陈文瑛,唐富天,陈少锐,刘培庆.丹参酮ⅡA对动脉粥样硬化的防御作用研究[J].中国药房,2008,19(12):884-888. 被引量：26
  • 7古练权,刘培庆,李贵华.丹参酮IIa用于制备预防和治疗动脉粥样硬化的药物.中国专利:CNl426782,2003-07-02.
  • 8Saito S, Takayama T, Honye Jet al. Effect of lipid-lowering therapy on plague volume and composition in patient with coronary artery diseaseevaluated by three dimensional intravascular ultrasound.中国循环杂志,2002.11:143—145.

二级参考文献23

  • 1黄熙,臧益民.丹参酮ⅡA磺酸钠心血管药理[J].国外医学（中医中药分册）,1995,17(1):9-12. 被引量：66
  • 2孙明谨,李雪锋,陈世清,胡清,王芳,朱大菊.2型糖尿病血清C反应蛋白及血白细胞变化[J].中国医师杂志,2005,7(11):1557-1558. 被引量：19
  • 3VozarovaB,WeyerC.lindsayRS,et al.Highwhite blood cell count is associated with a worsering of insulin sensitivity and predicts.The development of typez diabetes.Diabetes,2002,51:455-461.
  • 4李家实.中药鉴定学[M].上海：上海科学技术出版社,1998.340-341.
  • 5Freeman DJ, Norrie J, Caslake MJ, et al.C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study [J].Diabetes,2002,51(5):1596-1600.
  • 6Vozarova B, Weyer C, Lindsay RS, et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes [J].Diabetes,2002,51(2):455-461.
  • 7Andreas F,Ralph DA,George H,et al.Chronic subclinical inflammation as part of the insulin resistance syndrome [J].Circulation,2000,102(1):42-47.
  • 8Ridker PM, Hernnekens CH, Buring JE, et a1.C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J].N Ensi JMed,2002,342(12):836-843.
  • 9Festa A, D Agostino R Jr,Tracy RP,et a1.Elevatedlevels of acute_phase proteins and plasminogen activator inhabitorl-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study[J].Diabetes,2002,51:1 131-1 137.
  • 10Spranger J, Kroke AM. Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes: Results of the Prospective population-Based European Prospective Investigation into Cancerand Nutrition(EPIC). Potsdamstudy[J]. Diabetes, 2003, 52(3):812-817.

共引文献49

同被引文献21

  • 1Valerio G, Bracciale P,Grazia D' Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease[J]. Ther Adv Respir Dis,2009,3(1) :15-21.
  • 2Bull T, Badesch D B. Sildenafil for COPD: a randomized crossover trial[J]. COPD,2012,9(3) :211-212.
  • 3Wu W Y,Yan H,Wang X B,et al. Sodium tanshinone Ⅱ A silate inhibits high glucose-induced vascular smooth muscle cell proliferation and migration through activation of AMP-activated protein kinase[J]. PLoS One, 2014,9 (4) : e94957.
  • 4Yang R,Liu A,Ma X,et al. Sodium tanshinone Ⅱ A sulfonate protects eardiomyoeytes against oxidative stress-mediated apoptosis through inhibiting JNK activation [J]. J Cardiovasc Pharmaeol, 2008,51 (4) : 396-401.
  • 5Luo Y,Xu D Q,Dong H Y,et al. Tanshinone Ⅱ A inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via Akt/SKP2/P27-associated pathway[J]. PLoS One, 2013,8(2) :e56774.
  • 6Raja S G. Sodium tanshinone Ⅱ A sulfonate for pulmonary arterial hypertension:emerging therapeutic option[J]. J Thorac Dis,2013,5(2) :114-115.
  • 7Huang Y F,Liu M L,Dong M Q,et al. Effects of sodium tanshinone Ⅱ A sulphonate on hypoxie pulmonary hypertension in rats in vivo and on Kv2. 1 expression in pulmonary artery smooth muscle cells in vitro[J]. J Ethnopharmacol, 2009,125 (3) :436-443.
  • 8Wang J,Dong M Q,Liu M L,et al. Tanshinone Ⅱ A modulates pulmonary vascular response to agonist and hypoxia primarily via inhibiting Ca^2+ influx and release in normal and hypoxic pulmonary hypertension rats[J]. Eur J Pharmacol, 2010, 640 (1-3) :129-138.
  • 9Wang J, Lu W, Wang W, et al. Promising therapeutic effects of sodium tanshinone Ⅱ A sulfonate towards pulmonary arterial hypertension in patients[J]. J Thorac Dis, 2013,5 (2) : 169-172.
  • 10郭庆.丹参酮Ⅱa磺酸钠注射液治疗急性冠脉综合征临床观察[J].中外医疗,2010,29(12):101-101. 被引量：1

引证文献2

二级引证文献17

浙江临床医学
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部